Click to download Insight into Why Quality Healthcare Provider Data Is So Elusive

THE DYNAMIC NATURE OF HEALTHCARE PROVIDER DATA: Why ongoing assessments are key to data quality.

By Theresa Greco, Vice President, Client Solutions, and Abigail Hardy, Life Sciences Lead, Client Solutions
Health Market Science recently released important analyses on why healthcare provider data is so difficult to get and maintain, what can be done to remedy the data status quo and why it’s gone from desirable to must have in an increasingly regulated environment. Consider just a few of the statistics you’ll find in the white paper:

• >85% of provider records match to an authoritative record
  15% of records are for inactive providers –retired or outdated credentials associated with provider moves
• 1% of the records are for deceased providers
• 1% of records are for providers who were presumed vetted, but who were sanctioned

Understanding the condition and nature of your provider data will help keep your organization on the path to improved business performance and risk mitigation.

Click Here to Download the White Paper "Drug Sample Acceptance Preferences in Medical Offices"

White Paper: Drug Sample Acceptance Preferences in Medical Offices

Published by SK&A, A Cegedim Company

Learn which physicians accept and store drug samples at their office sites, and their preferences for receiving the sample packets from pharmaceutical sales reps. SK&A, A Cegedim Company’s recent telephone survey of nearly 170,000 U.S. medical offices reveals an average acceptance rate of 77 percent. Download this unique report to understand acceptance preferences by specialty, patient volume, practice size and ownership. Determine if your targets prefer to have drug samples dropped off, mailed or both.

Click the title to download the New Medical Marketing Economics Whitepaper!

IOM Comparative Effectiveness Research: Implications for Pharma Brand Teams
The Institute of Medicine (IOM) recently released its recommendation on the topics to study for comparative effectiveness. Many feared that this work would result in restrictions on the use of many prescription drugs and pressures for reduced prices.

To help pharmaceutical marketers to understand the potential impact of comparative effectiveness research (CER) on their business, Medical Marketing Economics has undertaken an in-depth analysis of the IOM report and is pleased to say that except for a few cases, prescription drugs in general are much more likely to benefit from these studies than to be harmed. Nine specific categories of drugs were listed to be evaluated for effectiveness among the 100 research initiatives outlined, and their priorities for evaluation are displayed in the graphic presented here.